| Bioactivity | SAHA-OH is a selective HDAC6 inhibitor (IC50=23 nM), shows a 10- to 47-fold selectivity for HDAC6 compared to HDAC 1, 2, 3, and 8. SAHA-OH shows anti-inflammatory activity, and attenuates macrophage apoptosis[1]. |
| Invitro | SAHA-OH (0.67-10.76 μM; 51 h) shows inhibition in bone marrow macrophages[1].SAHA-OH (0.01 μM; 3 h) treatment in BMMØs (bone marrow macrophages) reduces IL-6, TNFα, IFNβ, IL-1β, IL-10, MCP-1 (CCL2) and GROα (CXCL1) secretions[1].SAHA-OH (10 μM; 4 or 9 h) treatment induces acetylation of cytoplasmic α-tubulin and nuclear histone H3[1].SAHA-OH (0-30 μM; 3 h) treatment attenuates macrophage apoptosis[1].SAHA-OH (0-30 μM; 3 h) treatment attenuates B cell death[1]. Cell Viability Assay[1] Cell Line: |
| In Vivo | SAHA-OH (intraperitoneal injection; 50 mg/kg; once) treatment prevents splenic organ damage, and reduces plasma proinflammatory cytokine levels in LPS-induced endotoxemia mouse model[1]. Animal Model: |
| Name | SAHA-OH |
| Formula | C15H22N2O4 |
| Molar Mass | 294.35 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Nhu Truong, et al. Modified Suberoylanilide Hydroxamic Acid Reduced Drug-Associated Immune Cell Death and Organ Damage under Lipopolysaccharide Inflammatory Challenge. ACS Pharmacol. Transl. Sci. 2022. |